Fortive Corp FTV 深 沪
交易中 12-30 10:58:09 美东时间
56.07
-0.080
-0.14%
华盛通- 最 高56.19
- 今 开56.00
- 成交量 23.43万股
- 最 低 55.905
- 昨 收 56.15
- 总市值 178.30亿
- 52周最高 65.38
- 市盈率 静 23.75
- 换手率 0.07%
- 52周最低 42.525
- 委 比 80.25%
- 总股本 3.18亿
- 历史最高 68.92
- 量 比 0.69
- 振 幅 0.51%
- 历史最低 4.59
- 每 手 1
- 风险率 4.76%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅498.16%！SurgePays Inc获Ascendiant Capital升目标价至9.75美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持SurgePays Inc"买入"评级，目标价从9.5美元升至9.75美元；Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从8美元升至10美元
12-23 12:32
Wells Fargo Maintains Equal-Weight on Fortive, Raises Price Target to $59
Wells Fargo analyst Joseph O'Dea maintains Fortive (NYSE:FTV) with a Equal-Weight and raises the price target from $55 to $59.
12-22 22:39
GXO Announces Brad Jacobs Will Step Down as Non-Executive Chairman
GXO Logistics announced that Patrick Byrne will replace Brad Jacobs as Non-Executive Chairman effective December 31, 2025. This change follows significant transformations at the company, including new leadership appointments and the acquisition of Wincanton. Byrne, with over 30 years of experience in digital transformation and operational leadership, joins the board and looks forward to driving growth and value creation for GXO.
12-15 12:00
美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
12-09 10:32
Citigroup Maintains Neutral on Fortive, Raises Price Target to $59
Citigroup analyst Andrew Kaplowitz maintains Fortive (NYSE:FTV) with a Neutral and raises the price target from $57 to $59.
12-09 03:18
Dan Loeb Raises Microsoft Stake 175% In Big-Tech Push, Dumps Workday And More
Dan Loeb's Third Point doubled its Microsoft stake and boosted Meta, Amazon, and Nvidia while fully exiting Workday and multiple industrial names in Q3.
11-20 04:46
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
11-06 09:55
美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
11-05 10:35
美股大行评级 | 最高350美元！16家大行上调谷歌目标价！Meta遭12家大行下调目标价；潜在涨幅1456.29%！NRX Pharmaceuticals获Ascendiant Capital升目标价至47美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从46美元升至47美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从27美元升至31美元
10-31 10:25
